On Wednesday, Argus, a market research firm, adjusted its outlook on Cardinal Health (NYSE: NYSE:CAH) shares, reducing its price target to $115 from the previous $120 while reaffirming a Buy rating on the stock. The revision reflects the challenges and strategic moves made by the healthcare services giant.
Cardinal Health, recognized as one of the leading distributors of pharmaceuticals in the United States and a significant global player in medical and laboratory product manufacturing and distribution, has seen its Pharmaceutical segment rebound from the impacts of the pandemic.
However, the company's Medical segment is experiencing strain due to long-term distribution contracts that limit its ability to pass on increased costs to its customers.
The company is also navigating financial commitments stemming from the national opioid settlement, agreeing to pay up to $6 billion over the next 18 years. Amidst these pressures, activist investment firm Elliot Management has acquired a substantial stake in Cardinal Health.
Despite these hurdles, Cardinal Health has exhibited notable financial management, leveraging the strong cash flow from its generic program to amass a considerable cash reserve. This has enabled the company to buy back $750 million of its stock in the first half of the fiscal year.
Additionally, an acquisition made in the second fiscal quarter is anticipated to bolster the company's growth strategy, particularly in specialty products that carry higher margins.
The loss of a significant client recently posed a setback for Cardinal Health, yet the firm believes that the recent acquisition and the ongoing improvement in the medical business will compensate for this loss and contribute to growth in the fiscal year 2025.
InvestingPro Insights
Cardinal Health (NYSE: CAH) has been a topic of discussion among investors, especially given its strategic maneuvers and financial commitments. According to InvestingPro data, the company has a market capitalization of $23.73 billion and is trading at a P/E ratio of 43.61. However, when adjusted for the last twelve months as of Q3 2024, the P/E ratio becomes more favorable at 15.53, reflecting a more attractive valuation for investors. The company also boasts a solid revenue growth of 11.03% for the same period, indicating a strong business performance.
InvestingPro Tips suggest that Cardinal Health's management is actively buying back shares and has consistently raised its dividend for over three decades, with a current dividend yield of 2.08%. Moreover, analysts expect net income growth this year, underscoring the company's potential for profitability in the near term. For investors seeking further insights and additional tips, there are 17 more InvestingPro Tips available for Cardinal Health, which can be accessed by using the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
These data points and tips can help investors better understand Cardinal Health's current financial health and market position, providing valuable context to the company's recent activities and future prospects as outlined in the article.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.